You may be trying to access this site from a secured browser on the server. Please enable scripts and reload this page.
Turn on more accessible mode
Turn off more accessible mode
Skip Ribbon Commands
Skip to main content
Turn off Animations
Turn on Animations
Sign In
This page location is:
Lab Test Reference Manual
Human Reference Manual
Pages
22565
Lab Test Reference Manual
Human Reference Manual
Currently selected
22565
Digoxin
Marshfield Lab Public WebSite
Marshfield Clinic Public WebSite
It looks like your browser does not have JavaScript enabled. Please turn on JavaScript and try again.
Search
Test Code
Laboratory Section
All
Test Category
All
Browse By Test Name
#
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
Additional Information
Libraries
Newsletter Document Library
Regional Menus Pages
Lists
Lab Clinical Practice Guidelines
Antimicrobial Susceptibility Panels
Toxicology Information
Urine Preservatives
Requisition Forms and Instructions
Testing
Newsletter Links
Newsletters 2014
Newsletters 2015
Newsletters 2016
Newsletters 2017
Newsletters 2018
Cumulative Antibiogram Reports
testz
Human Test Code IDs
Recent
Newsletters 2025
Newsletters 2024
Newsletters 2023
Newsletters 2022
Antibiogram-PDFs
Site Contents
Digoxin
Test Code: DIGOX
Overview
Ordering
Specimen
Performing
Clinical/Interpretive
Contacts
Coding
Synonyms/Keywords
Synonyms, Keywords
Lanoxin, DIG, Digitalis
Useful For
Useful For
Digoxin, which improves the pumping action of the heart, is an inotropic agent. It is the cardiac glycoside most frequently prescribed for the treatment of congestive heart failure and disorders characterized by abnormal heart rate. Digoxin functions by stimulating the contraction of heart muscle and slowing ventricular rate. Toxicity is frequently of concern.
Specimen Requirements
Specimen Requirements
Fasting Required
Specimen Type
Preferred Container/Tube
Acceptable Container/Tube
Specimen Volume
Specimen Minimum Volume
(allows for 1 repeat)
Pediatric Minimum Volume
(no repeat)
No
Plasma/Serum
Lithium-heparin Plasma Separator (PST), Serum Separator Tube (SST)
Lithium or Sodium-heparin Green Top (GTT), Red Top Tube (RTT)
1 mL
0.3 mL
0.6 mL whole blood
Collection Processing Instructions
Collection Processing
Collect specimen no sooner than 8 hours after last dose.
Remove sample from cells as soon as possible after collection.
Plasma/serum must be removed from gel within 24 hours of collection.
Specimen Stability Information
Specimen Stability Information
Specimen Type
Temperature
Time
Plasma/Serum
Refrigerate
7 days
Frozen
1 year
Rejection Criteria
Rejection Criteria
Plasma/serum not removed from gel within 24 hours of collection.
Interference
Interference
For testing performed at Weston: High doses of exogenous biotin (also termed Vitamin B7, Vitamin H or Coenzyme R) may interfere with this assay. It is recommended that patients refrain from consuming any multivitamin or supplement containing biotin for at least 72 hours prior to collection of a blood sample.
Performing Laboratory Information
Performing Laboratory Information
Performing Location
Day(s) Test Performed
Analytical Time
Methodology/Instrumentation
Weston
Monday through Sunday
Less than 2 hours
Immunoassay Technique/Siemens Dimension
Eau Claire
Monday through Sunday
Less than 2 hours
Immunoassay Technique/Siemens Dimension
Lakeview Medical Center
Monday through Sunday
Less than 2 hours
Immunoassay Technique/Siemens Dimension
Marshfield
Monday through Sunday
Less than 2 hours
Emit*2000 Rate Assay/Beckman AU
Minocqua
Monday through Sunday
Less than 2 hours
Immunoassay Technique/Siemens Dimension
Test Information
Test Information
Monitor serum level 8-24 hours after dosing (either oral or IV), or before administration of next dose. At this interval, equilibration with tissues is optimal and levels will correlate best with cardiac activity. With normal renal function, time to a new steady state level is 5 days - 2 weeks (or longer with reduced renal function or congestive heart failure).
Half life (healthy adult): 30 - 35 hours.
Time to peak level: Plasma = 2 - 3 hours after last dose; Tissues = at least 8 hours after last dose. Quinidine, verapamil, amiodarone or flecainide decrease clearance of digoxin and increase plasma levels.
Reference Range Information
Reference Range Information
Performing Location
Reference Range
All Performing Sites
Therapeutic: 0.5-2.0 ng/mL
See Critical Value List for list of current critical values
Outreach CPTs
Outreach CPT Codes
CPT
Modifier
(if needed)
Quantity
Description
Comments
80162
Synonyms/Keywords
Synonyms, Keywords
Lanoxin, DIG, Digitalis
Ordering Applications
Ordering Applications
Ordering Application
Description
Centricity
a. Digoxin (Lanoxin)
b. Lanoxin (Digoxin)
c. Digoxin
Cerner
Digoxin Level
COM
Digoxin
If the ordering application you are looking for is not listed, contact your local laboratory for assistance.
Specimen Requirements
Specimen Requirements
Fasting Required
Specimen Type
Preferred Container/Tube
Acceptable Container/Tube
Specimen Volume
Specimen Minimum Volume
(allows for 1 repeat)
Pediatric Minimum Volume
(no repeat)
No
Plasma/Serum
Lithium-heparin Plasma Separator (PST), Serum Separator Tube (SST)
Lithium or Sodium-heparin Green Top (GTT), Red Top Tube (RTT)
1 mL
0.3 mL
0.6 mL whole blood
Collection Processing
Collection Processing
Collect specimen no sooner than 8 hours after last dose.
Remove sample from cells as soon as possible after collection.
Plasma/serum must be removed from gel within 24 hours of collection.
Specimen Stability Information
Specimen Stability Information
Specimen Type
Temperature
Time
Plasma/Serum
Refrigerate
7 days
Frozen
1 year
Rejection Criteria
Rejection Criteria
Plasma/serum not removed from gel within 24 hours of collection.
Interference
Interference
For testing performed at Weston: High doses of exogenous biotin (also termed Vitamin B7, Vitamin H or Coenzyme R) may interfere with this assay. It is recommended that patients refrain from consuming any multivitamin or supplement containing biotin for at least 72 hours prior to collection of a blood sample.
Useful For
Useful For
Digoxin, which improves the pumping action of the heart, is an inotropic agent. It is the cardiac glycoside most frequently prescribed for the treatment of congestive heart failure and disorders characterized by abnormal heart rate. Digoxin functions by stimulating the contraction of heart muscle and slowing ventricular rate. Toxicity is frequently of concern.
Reference Range Information
Reference Range Information
Performing Location
Reference Range
All Performing Sites
Therapeutic: 0.5-2.0 ng/mL
See Critical Value List for list of current critical values
For more information visit:
http://labtestsonline.org
Performing Laboratory Information
Performing Laboratory Information
Performing Location
Day(s) Test Performed
Analytical Time
Methodology/Instrumentation
Weston
Monday through Sunday
Less than 2 hours
Immunoassay Technique/Siemens Dimension
Eau Claire
Monday through Sunday
Less than 2 hours
Immunoassay Technique/Siemens Dimension
Lakeview Medical Center
Monday through Sunday
Less than 2 hours
Immunoassay Technique/Siemens Dimension
Marshfield
Monday through Sunday
Less than 2 hours
Emit*2000 Rate Assay/Beckman AU
Minocqua
Monday through Sunday
Less than 2 hours
Immunoassay Technique/Siemens Dimension
For billing questions, see Contacts
Outreach CPTs
Outreach CPT Codes
CPT
Modifier
(if needed)
Quantity
Description
Comments
80162
Return To Top
For most current information refer to the Marshfield Laboratory online reference manual.